Nanotechnology biopharmaceutical company: NanoViricides, Inc. (NNVC)

NanoViricides, Inc. (AMEX:NNVC) was founded in 2005 and is headquartered in Shelton, Connecticut, USA. It has 7 full-time employees. It is a nano-biopharmaceutical company that discovers, develops and commercializes nano-therapeutics for the treatment of viral infections.


NanoViricides, Inc. (NNVC):

NanoViricides is a development stage company with unique nanomedicine technology. The company is developing bionic antiviral drugs based on nanotechnology, which the company calls “nanoviricides®”. The company develops virus-specific nanokiller candidates for five commercially important viral diseases, including: seasonal and potentially epidemic influenza and avian influenza, HIV/AIDS, cold sores and genital herpes infections, viral eye diseases, and dengue fever The virus has proven to be very effective.

NanoViricides is developing anti-influenza drug candidates in the preclinical and advanced preclinical stages, including:

  1. Two FluCide drugs: 1) NV-INF-2, an oral anti-flu drug; NV-INF-1, an injectable anti-flu drug for H7N9, avian influenza H5N1 and other highly pathogenic influenza.
  2. HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate, can provide functional treatment for HIV/AIDS.
  3. HerpeCide, a skin cream or gel formulation used to treat oral and genital herpes virus infections.
  4. Eye drops fight against viral infections of the outer eye, and participate in other research projects against rabies virus, Ebola virus and Marburg virus.
Notify of
Inline Feedbacks
View all Intels

Enterprise Electronic Payment Processing: Payment Data System Usio, Inc. (USIO)

Document management software company: GlobalSCAPE, Inc. (GSB)